GlassScriptPhysician profile
Narges Mazloom
NPI 1003012642
$2,955.55
in general payments reported to CMS, 2019-2025
15 companies · $97.97 in 2025
The $97.97 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.02 · 2020: $13.69 · 2021: $327 · 2022: $205 · 2023: $82.61 · 2024: $2,194 · 2025: $97.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,307 · Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,306.92 |
| Food and Beverage | $1,067.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,819.09 | 2024-2025 | Scopis Ent, Clarifix Cryotherapy Device, Xpress Loprofile |
| Inspire Medical Systems, INC. | $570.71 | 2021-2024 | Inspire |
| Amgen INC. | $260.31 | 2024 | Repatha |
| Acclarent, INC | $59.53 | 2021 | |
| Smith+Nephew, INC. | $48.31 | 2020-2025 | Tula, Pico 14, Renasys Touch |
| Regeneron Healthcare Solutions, INC. | $36.50 | 2024 | Dupixent |
| Glaxosmithkline, LLC. | $35.84 | 2022-2023 | Nucala |
| Intersect Ent, INC. | $18.68 | 2019 | |
| Ambu INC. | $17.68 | 2021 | |
| Genzyme Corporation | $17.51 | 2021 | |
| Aerin Medical INC. | $16.34 | 2019 | |
| Acera Surgical, INC. | $15.26 | 2025 | Restrata Wound Matrix |
| Innovation Technologies INC | $14.84 | 2025 | Irrisept |
| Olympus America INC. | $13.58 | 2021 | |
| Medtronic, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narges Mazloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.